- Home
- ELVN vs MANE Comparison
ELVN vs MANE Comparison
Compare ELVN & MANE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ELVN | MANE |
|---|---|---|
| Founded | 2016 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.2B | 4.4B |
| IPO Year | 2020 | 2026 |
Fundamental Metrics
Financial Performance| Metric | ELVN | MANE |
|---|---|---|
| Price | $58.76 | $111.54 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 4 |
| Target Price | $43.40 | ★ $83.33 |
| AVG Volume (30 Days) | ★ 1.0M | 803.5K |
| Earning Date | 05-11-2026 | 03-30-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 3.17 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $14.79 | $36.26 |
| 52 Week High | $62.32 | $131.24 |
Technical Indicators
Market Signals| Indicator | ELVN | MANE |
|---|---|---|
| Relative Strength Index (RSI) | 62.42 | 53.30 |
| Support Level | $25.63 | $91.62 |
| Resistance Level | $62.32 | $114.50 |
| Average True Range (ATR) | 2.85 | 6.38 |
| MACD | -0.19 | 0.31 |
| Stochastic Oscillator | 64.44 | 83.35 |
Price Performance
Historical ComparisonAbout ELVN Enliven Therapeutics Inc.
Enliven Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of small molecule therapeutics. The product candidates of the company include ELVN-001 is designed to specifically target the BCR-ABL fusion gene product, the oncogenic driver for patients with chronic myeloid leukemia (CML), ELVN-002 is designed to inhibit wild-type HER2 and key mutations of HER2.
About MANE Veradermics Incorporated Common Stock
Veradermics Inc clinical-stage biopharmaceutical company focused on developing therapeutics to address pervasive treatment challenges in prevalent aesthetic and dermatological conditions. The company operates in a single segment of allocating resources, assessing performance, and making operating decisions.